Synthesis 2024; 56(04): 686-692
DOI: 10.1055/s-0040-1720087
special topic
Synthetic Development of Key Intermediates and Active Pharmaceutical Ingredients (APIs)

Exploratory Process Development of a Pulmonary Arterial Hypertension Clinical Compound via a Late-Stage Pd-Catalyzed Buchwald–Hartwig C–N Coupling

Russell F. Algera
,
Andrew Davidson
,
David K. Herbert
,
Yajing Lian
,
Fangfang Liu
,
Yiyang Liu
,
Asaad Nematalla
,
Jared L. Piper
,
Javier Magano
,
,
Bao Nguyen
,
Jeffrey W. Raggon
,
Joseph P. Rainville
,
Anil Rane
,
Yong Tao
,
Ke Wang
,
Hatice G. Yayla
Pfizer Inc.


Abstract

The development of a robust process for a Pd-catalyzed Buchwald–Hartwig C–N coupling reaction to manufacture PF-06842874, a clinical candidate for the treatment of pulmonary arterial hypertension, on kilogram scale is reported. The variability in reaction kinetics initially encountered was resolved via the use of sodium tert-butoxide as a homogeneous base and a careful selection of precatalyst by examination of the catalyst activation mechanism. Extraction with aqueous acid followed by careful pH adjustment allowed us to isolate the product with excellent purge of impurities. The process was successfully implemented in up to 18 kg demonstration.

Supporting Information



Publication History

Received: 08 June 2023

Accepted after revision: 31 July 2023

Article published online:
04 September 2023

© 2024. Thieme. All rights reserved

Georg Thieme Verlag KG
Rüdigerstraße 14, 70469 Stuttgart, Germany

 
  • References

    • 1a Humbert M, Sitbon O, Simmonneau G. N. Engl. J. Med. 2004; 351: 1425
    • 1b Lau EM. T, Giannoulatou E, Celermajer DS, Humbert M. Nat. Rev. Cardiol. 2017; 14: 603
    • 2a Duan S, Place D, Perfect HH, Ide ND, Maloney M, Sutherland K, Price Wiglesworth KE, Wang K, Olivier M, Kong F, Leeman K, Blunt J, Draper J, McAuliffe M, O’Sullivan M, Lynch D. Org. Process Res. Dev. 2016; 20: 1191
    • 2b Maloney M, Jones BP, Olivier M, Magano J, Wang K, Ide ND, Palm AS, Bill DR, Leeman KR, Sutherland K, Draper J, Daly AM, Keane J, Lynch D, O’Brien M, Tuohy J. Org. Process Res. Dev. 2016; 20: 1203
    • 2c Chekal BP, Ewers J, Guinness SM, Ide ND, Leeman KR, Post RJ, Rane AM, Sutherland K, Wang K, Webster M, Withbroe GJ, Draper J, Lynch D, McAuliffe M, Keane J. Org. Process Res. Dev. 2016; 20: 1217
  • 3 Weiss A, Neubauer MC, Yerabolu D, Kojonazarov B, Schlueter BC, Neubert L, Jonigk D, Baal N, Ruppert C, Dorfmuller P, Pullamsetti SS, Weissman N, Ghofrani H.-A, Grimminger F, Seeger W, Schermuly RT. Nat. Commun. 2019; 10: 2204
  • 4 Bhattacharya SK, Behenna DC, Cameron KO, Chen P, Curto JM, Freeman-Cook KD, Jalaie M, Kania RS, Lian Y, Nair SK, Palmer CL, Pettersson MY, Rui EY, Sammons M, Yang Q, Zhang L. Patent WO2020212865, 2020
  • 5 Beutner GL, Coombs JR, Green RA, Inankur B, Lin D, Qiu J, Roberts F, Simmons EM, Wisniewski SR. Org. Process Res. Dev. 2019; 23: 1529
  • 6 Yang Q, Sheng M, Huang Y. Org. Process Res. Dev. 2020; 24: 1586
  • 7 For an example of SNAr reaction of 1,2-amino alcohol at the nitrogen, see: Birman VB, Uffman EW, Jiang H, Li X, Kilbane CJ. J. Am. Chem. Soc. 2004; 126: 12226
  • 8 Zhou W, Fan M, Yin J, Jiang Y, Ma D. J. Am. Chem. Soc. 2015; 137: 11942
  • 9 Bernhardson DJ, Widlicka DW, Singer RA. Org. Process Res. Dev. 2019; 23: 1538
  • 10 See Supporting Information for details.
  • 11 Dallas AS, Gothelf KV. J. Org. Chem. 2005; 70: 3321
  • 12 Bruno NC, Tudge MT, Buchwald SL. Chem. Sci. 2013; 4: 916
  • 13 DeAngelis AJ, Gildner PG, Chow R, Colacot TJ. J. Org. Chem. 2015; 80: 6794
  • 14 We could also add the catalyst in portion to control the exotherm. This was not ideal, however, as prolonged exposure of chloropyridine to base leads to deacetylation impurity 7.
    • 15a Sharif S, Rucker RP, Chandrasoma N, Mitchell D, Rodriguez MJ, Froese RD, Organ MG. Angew. Chem. Int. Ed. 2015; 54: 9507
    • 15b Khadra A, Mayer S, Mitchell D, Rodriguez MJ, Organ MG. Organometallics 2017; 36: 3573
    • 15c Semeniuchenko V, Braje WM, Organ MG. Chem. Eur. J. 2021; 27: 12535
    • 15d Semeniuchenko V, Ovens JS, Braje WM, Organ MG. Organometallics 2021; 40: 3276
  • 16 NaBHT was formed in situ with BHT and NaOt-Bu with Keq > 4000 favoring NaBHT; see Supporting Information for details. Also see ref. 15d.
  • 17 Impurities: 4 LCAP, m/z = 360; 3 LCAP, m/z = 428, respectively.
  • 18 Prat D, Pardigon O, Flemming H.-W, Letestu S, Ducandas V, Isnard P, Guntrum E, Senac T, Ruisseau S, Cruciani P, Hosek P. Org. Process Res. Dev. 2013; 17: 1517
  • 19 We observed deacetylation impurity 8 when starting chloropyridine 2 is exposed to NaOt-Bu for 5 h.
  • 20 The 8 kg demonstration was carried out internally while the 18 kg demonstration was carried out externally, given limited internal capability caused by the COVID-19 crisis. The 18 kg demonstration afforded 1 as a yellow solid instead of the expected off-white solid. The discoloration was presumably due to poor pH control during basification. Thus, a more representative green chemistry analysis is obtained using our internal records for the 8 kg demonstration.